{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T20:06:45Z","timestamp":1777752405854,"version":"3.51.4"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","award":["2042022dx0003"],"award-info":[{"award-number":["2042022dx0003"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82473775"],"award-info":[{"award-number":["82473775"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82273774"],"award-info":[{"award-number":["82273774"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82503502"],"award-info":[{"award-number":["82503502"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82173676"],"award-info":[{"award-number":["82173676"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003819","name":"Natural Science Foundation of Hubei Province","doi-asserted-by":"publisher","award":["2025AFB254"],"award-info":[{"award-number":["2025AFB254"]}],"id":[{"id":"10.13039\/501100003819","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.bioorg.2025.109374","type":"journal-article","created":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T16:16:02Z","timestamp":1765556162000},"page":"109374","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Targeted degradation of estrogen receptor \u03b2 to overcome Osimertinib resistance in non-small cell lung carcinoma"],"prefix":"10.1016","volume":"168","author":[{"given":"Yunchong","family":"Meng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaofei","family":"Deng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Baohua","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Na","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaojun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shihao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chune","family":"Dong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongde","family":"Liao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hai-Bing","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2020","key":"10.1016\/j.bioorg.2025.109374_bb0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ccm.2019.10.001","article-title":"Epidemiology, Etiology, and prevention","volume":"41","author":"Bade","year":"2020","journal-title":"Clin. Chest Med."},{"key":"10.1016\/j.bioorg.2025.109374_bb0010","doi-asserted-by":"crossref","unstructured":"F. Bray, M. Laversanne, H. Sung, J. Ferlay, R.L. Siegel, I. Soerjomataram, A. Jemal, Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA Cancer J. Clin., 74 (2024) 229\u2013263.","DOI":"10.3322\/caac.21834"},{"key":"10.1016\/j.bioorg.2025.109374_bb0015","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.3892\/mmr.2014.2082","article-title":"Antitumor activity of combination treatment with gefitinib and docetaxel in EGFR-TKI-sensitive, primary resistant and acquired resistant human non-small cell lung cancer cells","volume":"9","author":"Wu","year":"2014","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.bioorg.2025.109374_bb0020","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1056\/NEJMra0802714","article-title":"Lung cancer","volume":"359","author":"Herbst","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bioorg.2025.109374_bb0025","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.lungcan.2017.05.009","article-title":"Optimal management of EGFR-mutant non-small cell lung cancer with disease progression on first-line tyrosine kinase inhibitor therapy","volume":"110","author":"Liao","year":"2017","journal-title":"Lung Cancer"},{"key":"10.1016\/j.bioorg.2025.109374_bb0030","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1200\/JCO.22.02186","article-title":"Adjuvant Osimertinib for resected EGFR-mutated stage IB-IIIA non-small-cell lung Cancer: updated results from the phase III randomized ADAURA trial","volume":"41","author":"Herbst","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bioorg.2025.109374_bb0035","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1177\/10781552211020798","article-title":"A real world analysis of first line treatment of advanced EGFR mutated non-small cell lung cancer: a multi-center, retrospective study","volume":"28","author":"Lee","year":"2022","journal-title":"J. Oncol. Pharm. Pract."},{"key":"10.1016\/j.bioorg.2025.109374_bb0040","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/s41571-022-00639-9","article-title":"Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management","volume":"19","author":"Cooper","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.bioorg.2025.109374_bb0045","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non-small-cell lung Cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bioorg.2025.109374_bb0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100280","article-title":"Treating disease progression with osimertinib in EGFR-mutated non-small-cell lung cancer: novel targeted agents and combination strategies","volume":"6","author":"Di Noia","year":"2021","journal-title":"ESMO Open"},{"key":"10.1016\/j.bioorg.2025.109374_bb0055","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1002\/med.21700","article-title":"Recent updates on the resistance mechanisms to epidermal growth factor receptor tyrosine kinase inhibitors and resistance reversion strategies in lung cancer","volume":"40","author":"Tripathi","year":"2020","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.bioorg.2025.109374_bb0060","first-page":"98","article-title":"Osimertinib + Savolitinib to overcome acquired MET-mediated resistance in epidermal growth factor receptor-mutated, MET-amplified non-small cell lung Cancer: TATTON, Cancer","volume":"13","author":"Hartmaier","year":"2023","journal-title":"Discovery"},{"key":"10.1016\/j.bioorg.2025.109374_bb0065","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1186\/s13046-017-0653-7","article-title":"Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines","volume":"36","author":"La Monica","year":"2017","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.bioorg.2025.109374_bb0070","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1158\/1535-7163.MCT-20-0229","article-title":"CH7233163 overcomes Osimertinib-resistant EGFR-Del19\/T790M\/C797S mutation","volume":"19","author":"Kashima","year":"2020","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bioorg.2025.109374_bb0075","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1021\/acsmedchemlett.8b00373","article-title":"Discovery of JND3229 as a new EGFRC797S mutant inhibitor with in vivo Monodrug efficacy","volume":"9","author":"Lu","year":"2018","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2025.109374_bb0080","doi-asserted-by":"crossref","first-page":"14633","DOI":"10.1021\/acs.jmedchem.3c01165","article-title":"Discovery of novel fourth-generation EGFR inhibitors to overcome C797S-mediated resistance","volume":"66","author":"Zhu","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109374_bb0085","first-page":"998","article-title":"PROTACs: An emerging therapeutic modality in precision medicine, cell","volume":"27","author":"Nalawansha","year":"2020","journal-title":"Chem. Biol."},{"key":"10.1016\/j.bioorg.2025.109374_bb0090","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41573-021-00371-6","article-title":"PROTAC targeted protein degraders: the past is prologue","volume":"21","author":"B\u00e9k\u00e9s","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bioorg.2025.109374_bb0095","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.pharmthera.2017.02.027","article-title":"Targeted protein degradation by PROTACs","volume":"174","author":"Neklesa","year":"2017","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.bioorg.2025.109374_bb0100","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1158\/1535-7163.MCT-21-0835","article-title":"HJM-561, a potent, selective, and orally bioavailable EGFR PROTAC that overcomes Osimertinib-resistant EGFR triple mutations","volume":"21","author":"Du","year":"2022","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bioorg.2025.109374_bb0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2023.126413","article-title":"Cetuximab-based PROteolysis targeting chimera for effectual downregulation of NSCLC with varied EGFR mutations","volume":"252","author":"Vartak","year":"2023","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.bioorg.2025.109374_bb0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113328","article-title":"Effective degradation of EGFR(L858R+T790M) mutant proteins by CRBN-based PROTACs through both proteosome and autophagy\/lysosome degradation systems","volume":"218","author":"Qu","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109374_bb0115","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1021\/acsmedchemlett.1c00645","article-title":"Design, synthesis, and biological evaluation of novel EGFR PROTACs targeting Del19\/T790M\/C797S mutation","volume":"13","author":"Zhang","year":"2022","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2025.109374_bb0120","doi-asserted-by":"crossref","first-page":"7283","DOI":"10.1021\/acs.jmedchem.4c00107","article-title":"Design, synthesis, and biological evaluation of novel EGFR PROTACs targeting C797S mutation","volume":"67","author":"Zhu","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109374_bb0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2023.216587","article-title":"USP7-mediated ERbeta stabilization mitigates ROS accumulation and promotes osimertinib resistance by suppressing PRDX3 SUMOylation in non-small cell lung carcinoma","volume":"582","author":"Meng","year":"2024","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bioorg.2025.109374_bb0130","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/s41419-022-04514-4","article-title":"Estrogen receptor beta promotes lung cancer invasion via increasing CXCR4 expression","volume":"13","author":"Liu","year":"2022","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.bioorg.2025.109374_bb0135","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1158\/1078-0432.CCR-10-0992","article-title":"Combined analysis of estrogen receptor beta-1 and progesterone receptor expression identifies lung cancer patients with poor outcome","volume":"17","author":"Stabile","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bioorg.2025.109374_bb0140","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1038\/s41388-018-0463-1","article-title":"Estrogen receptor beta promotes the vasculogenic mimicry (VM) and cell invasion via altering the lncRNA-MALAT1\/miR-145-5p\/NEDD9 signals in lung cancer","volume":"38","author":"Yu","year":"2019","journal-title":"Oncogene"},{"key":"10.1016\/j.bioorg.2025.109374_bb0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2019.115261","article-title":"Optimisation of estrogen receptor subtype-selectivity of a 4-aryl-4H-chromene scaffold previously identified by virtual screening","volume":"28","author":"Carr","year":"2020","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109374_bb0150","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1021\/jm201436k","article-title":"Diarylpropionitrile (DPN) enantiomers: synthesis and evaluation of Estrogen receptor \u03b2-selective ligands","volume":"55","author":"Carroll","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109374_bb0155","doi-asserted-by":"crossref","first-page":"5021","DOI":"10.1021\/jm049719y","article-title":"Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands","volume":"47","author":"Malamas","year":"2004","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109374_bb0160","doi-asserted-by":"crossref","first-page":"15106","DOI":"10.1021\/ja047633o","article-title":"Structure-based design of estrogen receptor-beta selective ligands","volume":"126","author":"Manas","year":"2004","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.bioorg.2025.109374_bb0165","doi-asserted-by":"crossref","first-page":"5021","DOI":"10.1021\/jm049719y","article-title":"Design and synthesis of aryl Diphenolic azoles as potent and selective Estrogen receptor-\u03b2 ligands","volume":"47","author":"Malamas","year":"2004","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109374_bb0170","doi-asserted-by":"crossref","first-page":"7124","DOI":"10.1073\/pnas.1521738113","article-title":"PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer","volume":"113","author":"Raina","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bioorg.2025.109374_bb0175","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1038\/s41568-021-00435-0","article-title":"The role of ROS in tumour development and progression","volume":"22","author":"Cheung","year":"2022","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bioorg.2025.109374_bb0180","doi-asserted-by":"crossref","first-page":"4081","DOI":"10.1158\/0008-5472.CAN-24-0249","article-title":"NUAK1-mediated phosphorylation of NADK mitigates ROS accumulation to promote Osimertinib resistance in non-small cell lung carcinoma","volume":"84","author":"Lin","year":"2024","journal-title":"Cancer Res."},{"key":"10.1016\/j.bioorg.2025.109374_bb0185","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13046-018-0728-0","article-title":"The interplay of reactive oxygen species and the epidermal growth factor receptor in tumor progression and drug resistance","volume":"37","author":"Weng","year":"2018","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.bioorg.2025.109374_bb0190","doi-asserted-by":"crossref","first-page":"9101","DOI":"10.1074\/jbc.M114.631580","article-title":"Gefitinib-mediated reactive oxygen specie (ROS) instigates mitochondrial dysfunction and drug resistance in lung cancer cells","volume":"290","author":"Okon","year":"2015","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bioorg.2025.109374_bb0195","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.freeradbiomed.2023.01.004","article-title":"Bazedoxifene-induced ROS promote mitochondrial dysfunction and enhance osimertinib sensitivity by inhibiting the p-STAT3\/SOCS3 and KEAP1\/NRF2 pathways in non-small cell lung cancer","volume":"196","author":"Meng","year":"2023","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.bioorg.2025.109374_bb0200","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/nchembio.1416","article-title":"The role of iron and reactive oxygen species in cell death","volume":"10","author":"Dixon","year":"2014","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.bioorg.2025.109374_bb0205","doi-asserted-by":"crossref","first-page":"986","DOI":"10.3390\/cancers13050986","article-title":"Oxidative stress in the tumor microenvironment and its relevance to Cancer immunotherapy","volume":"13","author":"Aboelella","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bioorg.2025.109374_bb0210","doi-asserted-by":"crossref","first-page":"1215524","DOI":"10.3389\/fonc.2023.1215524","article-title":"Impact of gender and mutational differences in hormone receptor expressing non-small cell lung cancer","volume":"13","author":"Hsu","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bioorg.2025.109374_bb0215","first-page":"33","article-title":"Open babel: An open chemical toolbox","volume":"3","author":"O\u2019Boyle","year":"2011","journal-title":"J. Chem."},{"key":"10.1016\/j.bioorg.2025.109374_bb0220","doi-asserted-by":"crossref","first-page":"3891","DOI":"10.1021\/acs.jcim.1c00203","article-title":"AutoDock Vina 1.2.0: new docking methods, expanded force field, and Python bindings","volume":"61","author":"Eberhardt","year":"2021","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.bioorg.2025.109374_bb0225","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/jcc.21334","article-title":"AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading","volume":"31","author":"Trott","year":"2010","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.bioorg.2025.109374_bb0230","doi-asserted-by":"crossref","unstructured":"K.J.C. Bowers, D. E.; Xu, H.; Dror, R. O.; Eastwood, M. P.; Gregersen, B. A.; Klepeis, J. L.; Kolossvary, I.; Moraes, M. A.; Sacerdoti, F. D.; Salmon, J. K.; Shan, Y.; Shaw, D. E., Scalable Algorithms for Molecular Dynamics Simulations on Commodity Clusters, Proceedings of the 2006 ACM\/IEEE Conference on Supercomputing, (2006) 84\u201397.","DOI":"10.1145\/1188455.1188544"}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206825012544?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206825012544?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T11:59:47Z","timestamp":1777463987000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206825012544"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":46,"alternative-id":["S0045206825012544"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2025.109374","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeted degradation of estrogen receptor \u03b2 to overcome Osimertinib resistance in non-small cell lung carcinoma","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2025.109374","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109374"}}